Quanterix Corporation reported third quarter 2025 revenue of $40.2 million, up 12.3% from $35.8 million in the prior year. GAAP gross margin was 42.8%, down from 56.3% the previous year, while adjusted gross margin (non-GAAP) was 45.9%, compared to 50.7%. The company reported an adjusted EBITDA (non-GAAP) loss of $11.9 million, compared to a loss of $5.5 million last year, mainly due to higher acquisition and restructuring charges. Cash, cash equivalents, marketable securities, and restricted cash totaled $138.1 million at quarter end. Adjusted cash usage for the quarter was $16.1 million, with expectations to end 2025 with approximately $120 million in cash and equivalents. Quanterix reiterated full-year 2025 revenue guidance of $130 to $135 million, or $165 to $170 million on a pro forma basis. The company expects to achieve $85 million in annualized synergies from the Akoya integration and reach cash flow breakeven in 2026. Business highlights include the integration of Akoya operations and sales teams, and progress in the Alzheimer's diagnostics segment.